Vascarta Targets Shared Pain Pathway with Transdermal Curcumin

Vascarta is positioning its lead candidate, VAS-101, as a non-opioid alternative for chronic pain by targeting a common inflammatory mechanism across sickle cell disease, chemotherapy-induced neuropathy, and osteoarthritis. The company reports that its transdermal delivery platform successfully bypasses the bioavailability issues that have historically limited oral curcumin treatments.

Money Talk·August 25, 2026·reads: 2,081

The therapeutic, known as Vasceptor, utilizes the proprietary Vasporta gel-based platform to deliver curcumin into the bloodstream. Researchers identified a shared molecular target across three distinct conditions: the IL-17A-driven TNF-α/p38 MAPK signaling cascade. This pathway acts as a central hub for nervous system sensitization, regardless of whether the initial trigger is hemolysis, chemotherapy-induced neurotoxicity, or joint inflammation.

Preclinical and early clinical data highlight the candidate's broad reach. In models of sickle cell disease, VAS-101 reduced axonal injury and markers of red blood cell instability. In cancer research, the gel mitigated cisplatin-induced hyperalgesia without interfering with the chemotherapy's antitumor effects. Furthermore, a Phase 1b trial in patients with knee osteoarthritis demonstrated significant pain reduction, with 40% of participants reporting meaningful improvement over 28 days.

Dr. Kalpna Gupta of the University of California, Irvine, noted that by disrupting this specific molecular signature, the treatment acts as a disease-modifying agent rather than a simple analgesic. Vascarta management plans to move forward with Investigational New Drug submissions, aiming to address the medical community's reliance on opioids for long-term pain management.